A novel chemoradiotherapy formulation developed by researchers at Indiana University School of Medicine and Purdue University uses radiation-controlled drug release technology that "provides more control on drug release and could also be applied to any type of solid tumor, such as those in the breast, prostate, lungs or the liver," said researcher You-Yeon Won. The formulation, tested on mouse models with human head and neck cancer, resulted in a reduction in chemoradiotherapy-related toxicities, paving the way for human trials, according to the study published in the Journal of Controlled Release.
New formulation tied to reduced chemoradiotherapy toxicities
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.